We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-6 of 6

Excessive pricing practices in pharmaceutical sector increasingly under the spotlight at EU and national level
  • Herbert Smith Freehills LLP
  • United Kingdom, European Union
  • May 16 2017

On 15 May 2017 the EU Commission announced that it has opened a formal investigation into the pricing practices of South African pharmaceutical


General Court upholds Commission decision in AstraZeneca abuse of dominance case
  • Herbert Smith Freehills LLP
  • European Union
  • July 2 2010

The General Court has issued its long awaited judgment in the AstraZeneca case, upholding the Commission's decision in respect of both the SPC abuse and the selective deregistration abuse.


ECJ ends Glaxo litigation saga by finding that a pricing restriction on parallel trade in pharmaceuticals has as its object the restriction of competition but that the commission needs to re-assess effects and efficiencies
  • Herbert Smith Freehills LLP
  • European Union
  • October 9 2009

In GlaxoSmithKline Services v Commission and Others, (Joined Cases C-50106 P and others), the ECJ states that the mere existence of an anticompetitive object is sufficient to trigger Article 81(1) EC without any further need to determine consumer harm.


The European Commission reports its findings on the pharmaceutical sector inquiry and details further action required
  • Herbert Smith Freehills LLP
  • European Union
  • July 10 2009

The European Commission has published its final report on the pharmaceutical sector inquiry, in which it concludes that there are a number of shortcomings in the way the market operates which require further action.


Advocate General finds that a pricing restriction on parallel trade in pharmaceuticals has as its object the restriction of competition
  • Herbert Smith Freehills LLP
  • European Union
  • July 2 2009

In GlaxoSmithKleine Services Unlimited v Commission and Others, (Joined Cases C-50106 P and others), Advocate General Verica Trstenjak delivered an Opinion which states that the mere existence of an anticompetitive object is sufficient to trigger Article 81(1) EC without any further determination of harm to the final consumers.